| Filed On | Filing |
|---|---|
| 19 Oct 2026 |
8-K: Other Events
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform |
| 04 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC. |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses |
| 09 Feb 2026 |
8-K: Shareholder Director Nominations
On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma |
| 05 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Houston, TX — November 5, 2025 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and s... |
| 06 Oct 2025 |
8-K: Other Events
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment |
| 26 Aug 2025 |
8-K: Regulation FD Disclosure
MARKER THERAPEUTICS CORPORATE PRESENTATION August 26, 2025 NASDAQ: MRKR |
| 12 Aug 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Marker Therapeutics, Inc. under Item 4.01 of its Form 8-K dated August 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with oth... |
| 17 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed wi... |
| 20 May 2025 |
8-K: Other Events
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma |
| 31 Mar 2025 |
8-K: Results of Operations and Financial Condition
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses |
| 27 Mar 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On March 21, 2025, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the stockholders considered one proposal, which is described in more detail in the Company’s definitive proxy statemen... |
| 19 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers. |
| 30 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers. |
| 23 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77... |
| 19 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77... |
| 17 Dec 2024 |
8-K: Other Events
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer |
| 14 Nov 2024 |
8-K: Results of Operations and Financial Condition
Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer |
Loading...